
SCLX Stock Forecast & Price Target
SCLX Analyst Ratings
Bulls say
Scilex Holding Co. is positioned favorably due to its ability to secure diversified revenue streams through strategic partnerships, which enhances its financial stability and supports ongoing research and development initiatives. The promising therapeutic profile of SP-102, characterized by its rapid onset and sustained efficacy, alongside a strong safety profile, distinguishes it in the market for pain management solutions. Additionally, the anticipated approval of ELYXYB® in Canada in early 2025 reinforces the company's growth potential, driven by its proprietary technology and strategic legal protections for its product pipeline.
Bears say
Scilex Holding Co's stock outlook appears negative due to a combination of market caution, which has led to a lower overall valuation, and investor sensitivity to broader financial conditions that adversely affect biotech companies. The company's connection to Sorrento Therapeutics raises concern, as Sorrento's own financial difficulties and liquidity issues may hinder Scilex's ability to establish itself as a standalone entity. Furthermore, the application of a 30% discount rate in valuation models reflects skepticism regarding Scilex's clinical pipeline and product commercialization prospects, compounding the factors contributing to its distressed valuation.
This aggregate rating is based on analysts' research of Scilex Holding Co and is not a guaranteed prediction by Public.com or investment advice.
SCLX Analyst Forecast & Price Prediction
Start investing in SCLX
Order type
Buy in
Order amount
Est. shares
0 shares